Literature DB >> 18753217

Identification of HLA-A*01- and HLA-A*02-restricted CD8+ T-cell epitopes shared among group B enteroviruses.

Andreas O Weinzierl1,2, Despina Rudolf2, Dominik Maurer2, Dorothee Wernet3, Hans-Georg Rammensee2, Stefan Stevanović2, Karin Klingel1.   

Abstract

Acute enteroviral infections ranging from meningitis, pancreatitis to myocarditis are common and normally well controlled by the host immune system comprising virus-specific CD8+ cytotoxic T lymphocytes (CTL). However, in some patients enteroviruses and especially coxsackieviruses of group B are capable of inducing severe chronic forms of diseases such as chronic myocarditis. Currently, it is not known whether divergences in the CTL-related immune response may contribute to the different outcome and course of enterovirus myocarditis. A pre-requisite for the study of CTL reactions in patients with acute and chronic myocarditis is the identification of CTL epitopes. In order to define dominant enterovirus CTL epitopes, we have screened, by using gamma interferon (IFN-gamma) ELISPOT, 62 HLA-A*01- and 59 HLA-A*02-positive healthy blood donors for pre-existing CTL reactions against 12 HLA-A*01 and 20 HLA-A*02 predicted CTL epitopes derived from coxsackieviruses of group B. Positive CTL reactions were verified by FACS analysis in a combined major histocompatibility complex-tetramer IFN-gamma staining. A total of 14.8% of all donors reacted against one of the three identified epitopes MLDGHLIAFDY, YGDDVIASY or GIIYIIYKL. The HLA-A*02-restricted epitope ILMNDQEVGV was recognized by 25% of all tested blood donors. For this peptide, we could demonstrate specific granzyme B secretion, a strong cytolytic potential and endogenous processing. All four epitopes were homologous in 36-92% of group B enteroviruses, providing a strong basis for monitoring the divergence of T-cell-based immune responses in enterovirus-induced acute and chronic diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753217     DOI: 10.1099/vir.0.2008/000711-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.

Authors:  Jeffrey S Kennedy; Marc Gurwith; Cornelia L Dekker; Sharon E Frey; Kathryn M Edwards; Julie Kenner; Michael Lock; Cyril Empig; Shigeru Morikawa; Masayuki Saijo; Hiroyuki Yokote; Kevin Karem; Inger Damon; Mark Perlroth; Richard N Greenberg
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

Review 2.  Type B coxsackieviruses and their interactions with the innate and adaptive immune systems.

Authors:  Christopher C Kemball; Mehrdad Alirezaei; J Lindsay Whitton
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

3.  POTN: A Human Leukocyte Antigen-A2 Immunogenic Peptides Screening Model and Its Applications in Tumor Antigens Prediction.

Authors:  Qingqing Meng; Yahong Wu; Xinghua Sui; Jingjie Meng; Tingting Wang; Yan Lin; Zhiwei Wang; Xiuman Zhou; Yuanming Qi; Jiangfeng Du; Yanfeng Gao
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

4.  Wild-type coxsackievirus infection dramatically alters the abundance, heterogeneity, and immunostimulatory capacity of conventional dendritic cells in vivo.

Authors:  Christopher C Kemball; Claudia T Flynn; Martin P Hosking; Jason Botten; J Lindsay Whitton
Journal:  Virology       Date:  2012-05-01       Impact factor: 3.616

5.  Differential interferon responses enhance viral epitope generation by myocardial immunoproteasomes in murine enterovirus myocarditis.

Authors:  Sandra Jäkel; Ulrike Kuckelkorn; Gudrun Szalay; Michael Plötz; Kathrin Textoris-Taube; Elisa Opitz; Karin Klingel; Stefan Stevanovic; Reinhard Kandolf; Katja Kotsch; Karl Stangl; Peter M Kloetzel; Antje Voigt
Journal:  Am J Pathol       Date:  2009-07-09       Impact factor: 4.307

Review 6.  Enterovirus infection and type 1 diabetes: unraveling the crime scene.

Authors:  T Rodriguez-Calvo
Journal:  Clin Exp Immunol       Date:  2018-11-13       Impact factor: 4.330

7.  The immunopeptidomic landscape of ovarian carcinomas.

Authors:  Heiko Schuster; Janet K Peper; Hans-Christian Bösmüller; Kevin Röhle; Linus Backert; Tatjana Bilich; Britta Ney; Markus W Löffler; Daniel J Kowalewski; Nico Trautwein; Armin Rabsteyn; Tobias Engler; Sabine Braun; Sebastian P Haen; Juliane S Walz; Barbara Schmid-Horch; Sara Y Brucker; Diethelm Wallwiener; Oliver Kohlbacher; Falko Fend; Hans-Georg Rammensee; Stefan Stevanović; Annette Staebler; Philipp Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-01       Impact factor: 11.205

8.  In silico and ex vivo approaches indicate immune pressure on capsid and non-capsid regions of coxsackie B viruses in the human system.

Authors:  Rhiannon Kundu; Robin Knight; Meenakshi Dunga; Mark Peakman
Journal:  PLoS One       Date:  2018-06-20       Impact factor: 3.240

9.  Coxsackievirus B3 inhibits antigen presentation in vivo, exerting a profound and selective effect on the MHC class I pathway.

Authors:  Christopher C Kemball; Stephanie Harkins; Jason K Whitmire; Claudia T Flynn; Ralph Feuer; J Lindsay Whitton
Journal:  PLoS Pathog       Date:  2009-10-16       Impact factor: 6.823

10.  Precise genotyping and recombination detection of Enterovirus.

Authors:  Chieh-Hua Lin; Yu-Bin Wang; Shu-Hwa Chen; Chao Agnes Hsiung; Chung-Yen Lin
Journal:  BMC Genomics       Date:  2015-12-09       Impact factor: 3.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.